Other OTC - Delayed Quote USD

BioInvent International AB (publ) (BOVNF)

4.7000 0.0000 (0.00%)
At close: July 29 at 12:25 PM EDT
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
61,153.0000
71,461.0000
326,126.0000
19,384.0000
147,372.0000
Operating Expense
440,485.0000
442,018.0000
376,598.0000
297,549.0000
222,329.0000
Operating Income
-379,332.0000
-370,557.0000
-50,472.0000
-278,165.0000
-74,957.0000
Net Non Operating Interest Income Expense
--
39,967.0000
8,422.0000
-253.0000
-307.0000
Pretax Income
-334,283.0000
-330,100.0000
-42,503.0000
-278,444.0000
-76,333.0000
Tax Provision
235.0000
204.0000
--
--
--
Net Income Common Stockholders
-334,518.0000
-330,304.0000
-42,503.0000
-278,444.0000
-76,333.0000
Diluted NI Available to Com Stockholders
-334,518.0000
-330,304.0000
-42,503.0000
-278,444.0000
-76,333.0000
Basic EPS
-5.08
-5.02
-0.69
-5.14
-2.66
Diluted EPS
-5.08
-5.02
-0.69
-5.14
-2.66
Basic Average Shares
65,822.9470
65,767.0000
61,521.0000
54,161.0000
28,716.0000
Diluted Average Shares
65,822.9470
65,767.0000
61,521.0000
54,161.0000
28,716.0000
Total Operating Income as Reported
-378,717.0000
-369,942.0000
-50,921.0000
-278,350.0000
-75,474.0000
Total Expenses
440,485.0000
442,018.0000
376,598.0000
297,549.0000
222,329.0000
Net Income from Continuing & Discontinued Operation
-334,518.0000
-330,304.0000
-42,503.0000
-278,444.0000
-76,333.0000
Normalized Income
-337,273.2000
-330,304.0000
-42,503.0000
-278,444.0000
-76,333.0000
Interest Income
--
40,605.0000
9,072.0000
264.0000
28.0000
Interest Expense
--
638.0000
650.0000
517.0000
335.0000
Net Interest Income
--
39,967.0000
8,422.0000
-253.0000
-307.0000
EBIT
-338,237.0000
-329,462.0000
-41,853.0000
-277,927.0000
-75,998.0000
EBITDA
-320,634.0000
-312,707.0000
-27,129.0000
-263,317.0000
-63,994.0000
Reconciled Depreciation
17,603.0000
16,755.0000
14,724.0000
14,610.0000
12,004.0000
Net Income from Continuing Operation Net Minority Interest
-334,518.0000
-330,304.0000
-42,503.0000
-278,444.0000
-76,333.0000
Total Unusual Items Excluding Goodwill
4,592.0000
--
--
--
--
Total Unusual Items
4,592.0000
--
--
--
--
Normalized EBITDA
-325,226.0000
-312,707.0000
-27,129.0000
-263,317.0000
-63,994.0000
Tax Rate for Calcs
0.0004
0.0002
--
--
--
Tax Effect of Unusual Items
1,836.8000
--
--
--
--
12/31/2020 - 9/3/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CASI CASI Pharmaceuticals, Inc.
2.4200
+5.22%
 
MRSN Mersana Therapeutics, Inc.
2.9400
+3.16%
 
CDTX Cidara Therapeutics, Inc.
12.63
-2.85%
 
VYGR Voyager Therapeutics, Inc.
7.62
+2.70%
 
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
 
CPRX Catalyst Pharmaceuticals, Inc.
14.89
+1.43%
 
AUPH Aurinia Pharmaceuticals Inc.
4.9100
+0.82%
 
ADMA ADMA Biologics, Inc.
6.55
+1.71%
 
MNKD MannKind Corporation
4.2300
+1.20%
 
ARDX Ardelyx, Inc.
6.42
+1.74%